The task of this Core is to provide well characterized, high-quality human-derived biospecimens required by the projects and to insure that longitudinal, structured, clinical information related to treatment and outcome is collected from the patient donors of those specimens. The primary substrate for these genetic characterization projects is a unique resource consisting of whole-organ maps that will provide histologic characterization and sufficient DNA and RNA to allow multiple experiments to be done on the same samples. This provides an unprecedented opportunity to cross-validate biologic insights coming from these different experimental platforms, and should provide, by far, the most complete view of urothelial carcinogenesis and progression ever realized. This Core will serve as a model for addressing the difficult problems of cross investigator and cross-institutional data exchange, issues of significant interest for the broader context of Texas cancer research. This Core will provide a web-based portal that will allow all investigators to browse and query the contents of the biorepository, de-identified clinical data, and translational research resources such as Standard Operating Procedures, reagent details, and primary datasets.
The specific aims for the core are as follows:
Specific Aim 1 : Provide pathologic review of all tissues.
Specific Aim 2 : Maintain a urothelial biospecimen repository, Specific Aim 3: Provide professional and technical services for the preparation and quality control of molecular analytes from the biospecimen repository.
Specific Aim 4 : Abstract clinical information for all patients providing biospecimens.
Specific Aim 5 : Capture longitudinal clinical follow-up on all patients providing biospecimens.
Specific Aim 6 : Assure that all information related to the SPORE Project is exchangeable.
Specific Aim 7 : Provide all SPORE Investigators with a common portal for access to Project data, including support for ad hoc query across projects and domains

Public Health Relevance

The projects of this SPORE will use human cancer bladder specimens and human bladder cancer cell lines for translational research directed toward improving the detection, prevention, and treatment of human bladder cancer. The Core will provide the investigators at The University of Texas MD Anderson Cancer Center as well as other collaborating institutions with high quality tissue samples from patients with bladder cancer diagnosed, treated, and followed in our institution. Standardized and centralized procedures have been established for tissue procurement, quality control, processing, storage, and distribution of samples to individual investigators. They will ensure optimal utilization of the samples according to the guidelines established by the Tissue Committee and IRB regulations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091846-13
Application #
8745036
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
City
Houston
State
TX
Country
United States
Zip Code
77030
Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Choi, Woonyoung; McConkey, David (2018) Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas D Eur Urol 73:e104-e105
Zhang, Miao; Adeniran, Adebowale J; Vikram, Raghunandan et al. (2018) Carcinoma of the urethra. Hum Pathol 72:35-44
Wang, Gang; Xiao, Li; Zhang, Miao et al. (2018) Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65
Zhang, Shizhen; Wang, Yan; Bondaruk, Jolanta et al. (2018) Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus :
Jazzar, Usama; Yong, Shan; Klaassen, Zachary et al. (2018) Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer 124:3127-3135
Westhoff, Ellen; Wu, Xifeng; Kiemeney, Lambertus A et al. (2018) Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer 142:1797-1804
Roth, Beat; Jayaratna, Isuru; Sundi, Debasish et al. (2017) Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget 8:34205-34222
Shore, Neal D; Boorjian, Stephen A; Canter, Daniel J et al. (2017) Intravesical rAd-IFN?/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 35:3410-3416
Lin, Moubin; Zhang, Liren; Hildebrandt, Michelle A T et al. (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8:74936-74946

Showing the most recent 10 out of 247 publications